ANTX Stock Price, AN2 Therapeutics, Inc. Quote, Chart

Market Summary

USD2.41+0.04

Market Closed

1.69%

ANTX Stock Price

View Fullscreen

ANTX RSI Chart

ANTX Valuation

Market Cap

71.7M

Price/Earnings (Trailing)

-1.11

Price/Sales (Trailing)

71.55

Price/Free Cashflow

-1.35

ANTX Price/Sales (Trailing)

ANTX Profitability

Return on Equity

-51.91%

Return on Assets

-46.66%

Free Cashflow Yield

-74.27%

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

ANTX Earnings

Earnings (TTM)

-64.7M

Earnings Growth (Yr)

-42.7%

Earnings Growth (Qtr)

-1.14%

Breaking Down ANTX Revenue

Last 7 days

-3.6%

Last 30 days

-28.5%

Last 90 days

-87.7%

Trailing 12 Months

-72.0%

How does ANTX drawdown profile look like?

ANTX Financial Health

Current Ratio

7.87

ANTX Investor Care

Shares Dilution (1Y)

53.25%

Diluted EPS (TTM)

-2.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	94.0K	307.0K	748.0K	1.4M
2021	0	0	0	69.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AN2 Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	krause kevin michael	acquired	-	-	30,000	chief strategy officer
Mar 15, 2024	eckburg paul	acquired	-	-	30,000	chief medical officer
Mar 15, 2024	chanda sanjay	acquired	-	-	27,500	chief development officer
Mar 15, 2024	eizen joshua m	acquired	-	-	30,000	chief legal officer
Mar 15, 2024	day lucy	acquired	-	-	27,500	chief financial officer
Mar 15, 2024	easom eric	acquired	-	-	99,000	chief executive officer

Which funds bought or sold ANTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	11.99	6,454,140	21,567,600	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	575,606	575,606	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	3,840,000	3,840,000	-%
Feb 15, 2024	BARCLAYS PLC	added	1,295	856,000	907,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	1,218,030	1,218,030	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	39.17	4,437,260	10,174,400	0.30%
Feb 14, 2024	Octagon Capital Advisors LP	reduced	-23.4	-333,464	13,617,100	2.18%
Feb 14, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	126,422	587,387	-%
Feb 14, 2024	Balyasny Asset Management L.P.	new	-	395,150	395,150	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	607	398,840	448,608	-%

Are Funds Buying or Selling ANTX?

Are funds buying ANTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANTX

No. of Funds

Unveiling AN2 Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	frazier life sciences public fund, l.p.	2.4%	707,879	SC 13G
Feb 14, 2024	ra capital management, l.p.	18.7%	5,551,295	SC 13G/A
Feb 14, 2024	citadel advisors llc	5.2%	6	SC 13G/A
Feb 14, 2024	pfizer inc	4.58%	1,362,499	SC 13G/A
Feb 13, 2024	easom eric	5.2%	1,572,170	SC 13G
Feb 12, 2024	janus henderson group plc	4.3%	1,279,975	SC 13G/A
Feb 09, 2024	adjuvant global health technology fund, l.p.	7.0%	2,080,051	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	9.0%	2,678,209	SC 13G/A
Jul 25, 2023	tcg crossover gp i, llc	6.6%	1,289,320	SC 13G
Jul 05, 2023	janus henderson group plc	5.1%	1,000,076	SC 13G

Recent SEC filings of AN2 Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	PRE 14A	PRE 14A
Mar 29, 2024	10-K	Annual Report
Mar 29, 2024	4/A	Insider Trading
Mar 29, 2024	4/A	Insider Trading
Mar 29, 2024	4/A	Insider Trading
Mar 29, 2024	4/A	Insider Trading
Mar 29, 2024	4/A	Insider Trading
Mar 29, 2024	4/A	Insider Trading
Mar 29, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to AN2 Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

AN2 Therapeutics, Inc. News

Latest updates

AN2 Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	35.2%	630	466	228	27.00	27.00	25.00	15.00	2.00
Operating Expenses	6.0%	12,476	11,770	10,333	7,683	7,594	6,932	4,998	2,050
S&GA Expenses	11.4%	3,724	3,342	3,635	2,050	1,782	1,587	898	401
R&D Expenses	17.8%	8,752	7,428	6,698	5,633	5,312	5,345	3,850	1,649
Net Income	-4.4%	-11,842	-11,339	-10,120	-7,655	-7,545	-6,943	-5,007	-2,048
Net Income Margin	38.1%	-30.32*	-49.01*	-105.09*	-288.83*	-312.22*	-	-	-
Free Cashflow	19.5%	-7,638	-9,487	-9,595	-6,742	-8,993	-4,691	-5,257	-1,543

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet									(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-9.8%	139	154	99.00	91.00	103	110	120	121	65.00
Current Assets	-12.6%	111	126	98.00	90.00	99.00	107	117	120	60.00
Cash Equivalents	-52.2%	16.00	33.00	41.00	27.00	27.00	29.00	41.00	83.00	12.00
Liabilities	-5.4%	14.00	15.00	11.00	9.00	7.00	4.00	4.00	5.00	3.00
Current Liabilities	-5.4%	14.00	15.00	11.00	9.00	7.00	4.00	4.00	5.00	3.00
Shareholder's Equity	-10.3%	125	139	88.00	83.00	95.00	106	116	115	-47.41
Retained Earnings	-12.3%	-154	-137	-120	-105	-89.72	-77.88	-66.54	-56.42	-47.38
Additional Paid-In Capital	0.8%	279	277	209	188	185	184	183	172	-
Shares Outstanding	0%	30.00	30.00	22.00	19.00	19.00	14.00	11.00	3.00	3.00
Float	-	-	-	109	-	-	-	119	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-44.6%	-17,068	-11,800	-12,824	-11,596	-7,638	-9,487	-9,595	-6,742	-8,993	-4,691	-5,257	-1,543
Share Based Compensation	2.9%	2,232	2,169	1,943	2,068	1,472	1,228	1,242	449	433	354	179	8.00
Cashflow From Investing	100.7%	420	-62,462	7,877	10,887	6,055	-2,317	-39,486	13,977	-	-	-	-
Cashflow From Financing	-100.5%	-321	66,066	19,050	199	-	-10.00	7,178	63,187	-969	-240	-	79,744

ANTX Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 54,871	$ 28,511
Research and development - related party		1,000
General and administrative	14,764	12,751
Total operating expenses	69,635	42,262
Loss from operations	(69,635)	(42,262)
Other income, net	4,903	1,306
Net loss	(64,732)	(40,956)
Accretion to redemption value and cumulative dividends on preferred stock		(1,820)
Net loss attributable to common stockholders	$ (64,732)	$ (42,776)
Net loss per share attributable to common stockholders, basic	$ (2.74)	$ (2.79)
Net loss per share attributable to common stockholders, diluted	$ (2.74)	$ (2.79)
Weighted-average number of shares used in computing net loss per share, basic	23,600,107	15,340,134
Weighted-average number of shares used in computing net loss per share, diluted	23,600,107	15,340,134
Other comprehensive loss:
Unrealized gain (loss) on investments	$ 649	$ (347)
Comprehensive loss	$ (64,083)	$ (41,303)

ANTX Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 15,647	$ 27,219
Short-term investments	91,648	68,840
Prepaid expenses and other current assets	3,212	2,509
Right-of-use asset, net		53
Total current assets	110,507	98,621
Long-term investments	27,194	3,219
Other assets, long-term	1,043	720
Total assets	138,744	102,560
Current liabilities:
Accounts payable	2,676	2,122
Accrued compensation	4,018	2,168
Accrued liabilities	6,681	2,837
Other current liabilities	666
Operating lease liabilities		53
Options subject to repurchase, short-term	2	6
Total current liabilities	14,043	7,186
Options subject to repurchase, long-term		2
Total liabilities	14,043	7,188
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.00001 par value; 500,000,000 shares authorized at December 31, 2023 and 2022; 29,741,445 and 19,402,658 shares issued and outstanding at December 31, 2023 and 2022, respectively
Additional paid-in capital	278,881	185,469
Accumulated other comprehensive gain (loss)	275	(374)
Accumulated deficit	(154,455)	(89,723)
Total stockholders' equity	124,701	95,372
Total liabilities and stockholders' equity	$ 138,744	$ 102,560

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

CEO	Mr. Eric E. Easom
WEBSITE	an2therapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	35

AN2 Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for AN2 Therapeutics, Inc.? What does ANTX stand for in stocks?

ANTX is the stock ticker symbol of AN2 Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AN2 Therapeutics, Inc. (ANTX)?

As of Tue Apr 23 2024, market cap of AN2 Therapeutics, Inc. is 70.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers. The fair value of AN2 Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AN2 Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AN2 Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANTX is over valued or under valued. Whether AN2 Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact AN2 Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANTX.

What is AN2 Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ANTX's PE ratio (Price to Earnings) is -1.09 and Price to Sales (PS) ratio is 71.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANTX PE ratio will change depending on the future growth rate expectations of investors.